| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Section of Hematology/Oncology, Department of Medicine, University of Chicago Cancer Research Center, University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois; 2 Environmental Epidemiology and Biostatistics, National Cancer Research Institute, Largo Rosanna Benzi, Genoa, Italy; 3 Department of Surgery, Division of Cardiovascular and Thoracic Surgery, University of Minnesota Medical School, Minneapolis, Minnesota; and 4 Department of Surgery, Division of Thoracic Surgery, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
Requests for reprints: Ravi Salgia, Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medical Center, Pritzker School of Medicine, 5841 South Maryland Avenue, MC2115, Chicago, IL 60637. Phone: 773-702-4399; Fax: 773-834-1798; E-mail: rsalgia{at}medicine.bsd.uchicago.edu.
c-Met receptor tyrosine kinase (RTK) has not been extensively studied in malignant pleural mesothelioma (MPM). In this study, c-Met was overexpressed and activated in most of the mesothelioma cell lines tested. Expression in MPM tissues by immunohistochemistry was increased (82%) in MPM in general compared with normal. c-Met was internalized with its ligand hepatocyte growth factor (HGF) in H28 MPM cells, with robust expression of c-Met. Serum circulating HGF was twice as high in mesothelioma patients as in healthy controls. There was a differential growth response and activation of AKT and extracellular signal–regulated kinase 1/2 in response to HGF for the various cell lines. Dose-dependent inhibition (IC50 < 2.5 µmol/L) of cell growth in mesothelioma cell lines, but not in H2052, H2452, and nonmalignant MeT-5A (IC50 >10 µmol/L), was observed with the small-molecule c-Met inhibitor SU11274. Furthermore, migration of H28 cells was blocked with both SU11274 and c-Met small interfering RNA. Abrogation of HGF-induced c-Met and downstream signaling was seen in mesothelioma cells. Of the 43 MPM tissues and 7 cell lines, we have identified mutations within the semaphorin domain (N375S, M431V, and N454I), the juxtamembrane domain (T1010I and G1085X), and an alternative spliced product with deletion of the exon 10 of c-Met in some of the samples. Interestingly, we observed that the cell lines H513 and H2596 harboring the T1010I mutation exhibited the most dramatic reduction of cell growth with SU11274 when compared with wild-type H28 and nonmalignant MeT-5A cells. Ultimately, c-Met would be an important target for therapy against MPM. (Cancer Res 2006; 66(1): 352-61
This article has been cited by other articles:
|
|
 |
|
  H Kothmaier, F Quehenberger, I Halbwedl, P Morbini, F Demirag, H Zeren, C E Comin, B Murer, P T Cagle, R Attanoos, et al. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors Thorax, April 1, 2008; 63(4): 345 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ye, D. Hu, L. Tu, X. Zhou, F. Lu, B. Wen, W. Wu, Y. Lin, Z. Zhou, and J. Qu Involvement of PI3K/Akt Signaling Pathway in Hepatocyte Growth Factor-Induced Migration of Uveal Melanoma Cells Invest. Ophthalmol. Vis. Sci., February 1, 2008; 49(2): 497 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Ramos-Nino, S. R. Blumen, T. Sabo-Attwood, H. Pass, M. Carbone, J. R. Testa, D. A. Altomare, and B. T. Mossman HGF Mediates Cell Proliferation of Human Mesothelioma Cells through a PI3K/MEK5/Fra-1 Pathway Am. J. Respir. Cell Mol. Biol., February 1, 2008; 38(2): 209 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jagadeeswaran, H. Surawska, S. Krishnaswamy, V. Janamanchi, A. C. Mackinnon, T. Y. Seiwert, S. Loganathan, R. Kanteti, T. Reichman, V. Nallasura, et al. Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion Cancer Res., January 1, 2008; 68(1): 132 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Ruhe, S. Streit, S. Hart, C.-H. Wong, K. Specht, P. Knyazev, T. Knyazeva, L. S. Tay, H. L. Loo, P. Foo, et al. Genetic Alterations in the Tyrosine Kinase Transcriptome of Human Cancer Cell Lines Cancer Res., December 1, 2007; 67(23): 11368 - 11376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Arena, A. Pisacane, M. Mazzone, P. M. Comoglio, and A. Bardelli Genetic targeting of the kinase activity of the Met receptor in cancer cells PNAS, July 3, 2007; 104(27): 11412 - 11417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jagadeeswaran, S. Jagadeeswaran, V. P. Bindokas, and R. Salgia Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1488 - L1494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cassinelli, C. Lanzi, G. Petrangolini, M. Tortoreto, G. Pratesi, G. Cuccuru, D. Laccabue, R. Supino, S. Belluco, E. Favini, et al. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol. Cancer Ther., September 1, 2006; 5(9): 2388 - 2397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mazzone and P. M. Comoglio The Met pathway: master switch and drug target in cancer progression FASEB J, August 1, 2006; 20(10): 1611 - 1621. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
